{"id":"W1972415660","doi":"10.1038/bjc.2014.494","title":"Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study","year":2014,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Gemcitabine; Rash; Pancreatic cancer; Erlotinib Hydrochloride; Internal medicine; Hazard ratio; Adverse effect; Clinical endpoint; Gastroenterology; Oncology; Confidence interval; Cancer; Epidermal growth factor receptor; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002211128,0.00015483,0.0008937462,0.0001190614,0.0003481243,0.00005396797,0.0002091552,0.00005317279,0.0002366009],"category_scores_gemma":[0.001520203,0.0001177665,0.0002083108,0.0002092185,0.00008274203,0.0001147599,0.00003829465,0.0002625444,0.000002221708],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002929414,"about_ca_system_score_gemma":0.0007546275,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007027588,"about_ca_topic_score_gemma":0.001557499,"domain_scores_codex":[0.997997,0.0001722025,0.0007310386,0.0002110321,0.0004919927,0.0003966616],"domain_scores_gemma":[0.9975734,0.0006879884,0.0003694867,0.0001845151,0.0009046915,0.0002799421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01178613,0.003332697,0.04638927,0.0006252865,0.002885732,0.0001077154,0.003594003,0.0005763443,0.002734696,0.00009796063,0.05181162,0.8760585],"study_design_scores_gemma":[0.2089876,0.04613024,0.5040684,0.003601603,0.01562723,0.001791458,0.003799309,0.03523524,0.0007780184,0.001782624,0.1772989,0.0008992724],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9729752,0.004340508,0.01297041,0.005480176,0.0003527312,0.003656223,0.00009949482,0.00001190464,0.0001133524],"genre_scores_gemma":[0.9888349,0.000666571,0.00383658,0.001047696,0.00126603,0.001271914,0.000009991235,0.00004207749,0.003024272],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8751593,"threshold_uncertainty_score":0.4802377,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05602157314813496,"score_gpt":0.4334477661941996,"score_spread":0.3774261930460646,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}